Background: Key criteria in the diagnostic workup and risk stratification for myeloproliferative neoplasms (MPN) include molecular testing for JAK2V617F and other mutant alleles. Multiple methods for quantitatively detecting nucleotide sequence changes exist, but the lower limit of detection can limit identification of the low-level allele fraction of a variant. We evaluated a recently developed blocker displacement amplification (BDA)-based quantitative PCR platform for detection and quantitation of JAK2V617F variant allele fraction (VAF).
Methods: Clinical samples were tested using BDA, next-generation sequencing (NGS), and droplet digital PCR (ddPCR) in a head-to-head comparison of sensitivity and specificity in detecting the JAK2V617F variant. In total, 112 human genomic DNA specimens previously tested for JAK2V617F gene mutation status with NGS were analyzed, including 12 samples with low-level variants with VAF ≤2%, 6 samples with VAF >2%, and 94 samples with no variant previously identified by NGS.
Results: BDA and ddPCR results correlated well across a range of VAFs, with both methods identifying the JAK2V617F variant down to at least 0.05% VAF. NGS of routine sequencing depth was less sensitive, identifying JAK2V617F only at 0.6% VAF.
Conclusions: BDA can provide a cost-effective alternative means to identify low-level variants using instrumentation commonly found in laboratories.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jalm/jfac130 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A rare case of concurrent JAK2V617F-positive essential thrombocythemia, multiple myeloma, and colorectal adenocarcinoma.
Indian J Pathol Microbiol
September 2024
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P. R. China.
Multiple myeloma (MM), essential thrombocythemia (ET), and colorectal adenocarcinoma (CA) are three distinct diseases. The co-occurrence of MM, ET, and CA in a single patient is exceedingly rare. Our study presents a remarkable case involving a 75-year-old patient who was simultaneously diagnosed with these three diseases.
View Article and Find Full Text PDFNeutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy.
Br J Haematol
December 2024
CRIMM, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Florence, Italy.
Article Synopsis
- The study compared the effects of Ropeginterferon alfa-2b (Ropeg) and phlebotomy-only (Phl-O) on the neutrophil-to-lymphocyte ratio (NLR) in 126 patients with low-risk polycythemia vera (PV).
- Results showed that Ropeg significantly reduced NLR, driven mainly by a drop in neutrophils, and this reduction correlated with better symptom management and lower JAK2 variant allele frequency.
- The findings suggest that monitoring NLR could be a useful tool for guiding Ropeg treatment in early-stage low-risk PV patients, particularly when distinguishing between treatment responders and non-responders.
Synergistic effect of concurrent high molecular risk mutations and lower JAK2 mutant variant allele frequencies on prognosis in patients with myelofibrosis-insights from a multicenter study.
Leukemia
January 2025
Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Article Synopsis
- High-molecular risk (HMR) mutations, such as ASXL1 and IDH, are linked to poorer outcomes in myelofibrosis (MF) patients, particularly when combined with lower levels of the JAK2V617F variant allele frequency (VAF).
- Analysis of 124 MF patients showed that HMR mutations significantly impacted prognosis for those with lower JAK2V617F VAF, while this effect was not observed in patients with higher VAF levels.
- The study's findings indicate that having both HMR mutations and a lower JAK2V617F VAF (≤50%) serves as a strong independent risk factor for survival, improving existing prognostic models and prompting the need for further
Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.
Blood Adv
October 2024
Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
Article Synopsis
- The COMBI II clinical trial evaluated the safety and efficacy of combining ruxolitinib and low-dose pegylated interferon alfa-2a in 25 patients with newly diagnosed polycythemia vera (PV) over two years.
- The results showed a high peripheral blood cell count remission rate of 92% and 56% of patients meeting remission criteria, with notable improvements in symptoms like abdominal discomfort and night sweats.
- Additionally, the treatment significantly decreased the JAK2V617F variant allele frequency, with 60% of patients achieving molecular remission, indicating effective outcomes with manageable toxicity.
Coexistence of BCR∷ABL1 translocation and JAK2V617F mutations in indian patients with myeloproliferative neoplasms: A case series.
Indian J Pathol Microbiol
July 2024
Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, Punjab, India.
BCR∷ABL1 translocation and JAK2V617F mutations are canonical variants of myeloproliferative neoplasms (MPNs). Traditionally considered mutually exclusive, they may rarely coexist. We report the clinicopathological profile and treatment outcomes of four MPN patients with coexistence of these disease-defining genetic variants.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!